Piper Sandler Maintains Overweight on argenx, Raises Price Target to $1350
Morgan Stanley Maintains Overweight on argenx, Lowers Price Target to $1130
argenx (ENXTBR:ARGX) Stock May Look Fully Priced Despite Its $1.15B Deal
argenx: Unnatural Products Deal Changes Risk Profile
Argenx to buy peptide platform in potentially billion-dollar deal
If You Invested $100 In argenx Stock 5 Years Ago, You Would Have This Much Today
3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade
Argenx to acquire biotech firm Unnatural Products for $1.15 billion
Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
Reported Saturday, argenx Plans To Submit Supplemental BLA For Efgartigimod In IMNM By End Of 2026 After Phase 3 ALKIVIA Shows 14.8-Point Greater TIS Improvement Versus Placebo At Week 52
Argenx To Acquire Unnatural Products For Up To ~$1.15B Including $550M Upfront And Up To $595M In Milestones, Adding Peptide Discovery Engine
argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
Best Biotech Stocks to Buy Now as AI Stocks Tank: ARGX
argenx to Present at Upcoming Investor Conferences
Citigroup Maintains Buy on argenx, Lowers Price Target to $1232
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
argenx (ENXTBR:ARGX) Stock Looks Overvalued After Its 202% Five Year Run
argenx (ENXTBR:ARGX) Posted Q3 2026 Results, Is It Fully Priced?
argenx (ENXTBR:ARGX) Reports Positive Phase 3 Data In Autoimmune Myositis
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.